Autolus Therapeutics plc (AUTL)
Develops engineered T cell therapies to treat blood cancers and autoimmune diseases.
$1.45-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-38.3%
The outlook
Analysts lean strongly bullish on AUTL, with an average price target implying roughly 490% upside from the current level. The stock is trading well below its short- and long-term moving averages and sits near the lower end of its 52-week range. Overall sentiment is neutral, reflecting the gap between analyst optimism and the stock's depressed technical positioning.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 8 analysts
Price trendBelow its 50- & 200-day averages
52-week range19% of the way from its 52-week low to high
Price targetAvg target +490% vs current price
Analyst price target
~12-month · 8 analysts$8.55average target+489.7% vs now
Now $1.45
Low $5.00High $11.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$385.9M
52-wk high
$2.60
52-wk low
$1.18
50-day avg
$1.58
200-day avg
$1.54
Trailing P/E
—